Characterizing Tissue Pathology

Offspring offers histopathology-based analyses of distribution and regulation of various biomarkers within normal and disease-affected human and animal tissues. We may also characterize the binding properties of low molecular drugs and biopharmaceutical drugs within such tissues, e.g. as support for demonstration of target engagement and off-target interactions and for development of ligands for PET imaging. To deliver informative value to such project it is paramount that data is generated in tissues that are well defined and pre-characterized for anatomical regions, tissue structures and location of specific cell types as well as distribution, state and type of ongoing disease processes. It is, moreover, essential to have a good understanding of the tissue quality (e.g. preservation of the tissue antigens) as failure to do so may severely impede correct interpretation of results in the above-mentioned studies

Characterizing Tissue Pathology
 

Our team has extensive pathology experience and skills to provide extremely detailed tissue characterizations

 

Procurement of tissues

We have many years of experience in procuring and evaluating tissues on behalf of our clients. We have a longstanding collaboration with the Netherlands Brain Bank which provides brain tissues of very high quality. We also work with leading global biospecimens providers for fresh, frozen and fixed human tissues.  Analyses can be performed on large cohorts of tissues provided by the client or by Offspring's collaborating partners for in vivo PKPD studies

Assessment of tissue quality

For this we have established IHC-based methods where new tissues are analyzed for detection of carefully selected biomarkers present in all tissues in a cell-specific manner.  Characterization of anatomical regions and organ structures are typically performed in tissue sections counterstained by hematoxylin-eosin

Characterization of disease process

Depending on the specific requirements we can characterize the disease process with pathological analyses on hematoxylin/eosin-counterstained tissue sections as well as with specific staining procedures for presence and distribution of cell and pathology-specific biomarkers. This includes among others IHC staining for markers of various immune cells, tissue destruction and local deposition of pathological byproducts (e.g. fibrillar amyloid beta, Tau, alpha-synuclein and huntingtin)